| A | B | C | |
|---|---|---|---|
| 1 | |||
| 2 | Brand Name | INCB7839 | |
| 3 | Generic Name | ||
| 4 | Indication | Solid Tumors, Breast Cancer | |
| 5 | Mechanism | Sheddase Inhibitor; synergy with herceptin given the ability to maintain HER2 on cells by inhibiting sheddase activity (which may make them more susceptible to Herceptin) | |
| 6 | Administration | MTD unknown | |
| 7 | Competition | ||
| 8 | Economics | ||
| 9 | IP | ||
| 10 | History | ||
| 11 | Clinical Trials | ||
| 12 | Phase Ib / IIa solid tumors | ||
| 13 | maximal tolerated dose has yet to be reached | ||
| 14 | |||
| 15 | Phase Ib / IIa Breast Cancer | ||
| 16 | plan initiation |